Subject(s)
Aggregatibacter actinomycetemcomitans/isolation & purification , Brain Abscess/microbiology , Gram-Positive Bacterial Infections/microbiology , Methanobrevibacter/isolation & purification , Pasteurellaceae Infections/microbiology , Adult , Aggregatibacter actinomycetemcomitans/genetics , Community-Acquired Infections/microbiology , DNA Restriction Enzymes/genetics , Female , Gram-Positive Bacterial Infections/diagnosis , Humans , Methane/analysis , Methane/biosynthesis , Methanobrevibacter/genetics , Pasteurellaceae Infections/diagnosis , Prospective StudiesABSTRACT
BACKGROUND: The use of rapid microbiological tests is supported by antimicrobial stewardship policies. Targeted antibiotic therapy (TAT) for community-acquired pneumonia (CAP) with positive urinary antigen test (UAT) has been associated with a favorable impact on outcome. We aimed to determine the factors associated with TAT prescription. PATIENTS AND METHODS: We conducted a retrospective multicenter study including all patients presenting with CAP and positive UAT for Streptococcus pneumoniae or Legionella pneumophila from January 2010 to December 2013. Patients presenting with aspiration pneumonia, coinfection, and neutropenia were excluded. CAP severity was assessed using the Pneumonia Severity Index (PSI). TAT was defined as the administration of amoxicillin for pneumococcal infection and either macrolides or fluoroquinolones (inactive against S. pneumoniae) for Legionella infection. RESULTS: A total of 861 patients were included, including 687 pneumococcal infections and 174 legionellosis from eight facilities and 37 medical departments. TAT was prescribed to 273 patients (32%). Four factors were found independently associated with a lower rate of TAT: a PSI score≥4 (OR 0.37), Hospital A (OR 0.41), hospitalization in the intensive care unit (OR 0.44), and cardiac comorbidities (OR 0.60). Four other factors were associated with a high rate of TAT: positive blood culture for S. pneumoniae (OR 2.32), Hospitals B (OR 2.34), E (OR 2.68), and H (OR 9.32). CONCLUSION: TAT in CAP with positive UAT was related to the hospitals as well as to patient characteristics.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antigens, Bacterial/urine , Antimicrobial Stewardship , Community-Acquired Infections/epidemiology , Legionella pneumophila/immunology , Legionnaires' Disease/epidemiology , Pneumonia, Pneumococcal/epidemiology , Streptococcus pneumoniae/immunology , Bacteremia/epidemiology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/microbiology , Community-Acquired Infections/urine , Comorbidity , Diagnostic Tests, Routine , Drug Substitution , Drug Therapy, Combination , Hospital Departments , Hospitalization , Humans , Intensive Care Units , Legionnaires' Disease/drug therapy , Legionnaires' Disease/urine , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/urine , Retrospective Studies , Risk FactorsABSTRACT
After an initial screening of ingredients and production methods, nanoemulsions for ocular administration of timolol containing the drug as maleate (TM) or as ion-pair with AOT (TM/AOT) were prepared. The physico-chemical characterization of nanoemulsions, regarding mean diameter, pH, zeta potential, osmolarity, viscosity and surface tension, underlined their feasibility to be instilled into the eyes. Single components and emulsions were tested ex vivo on rabbit corneas to evaluate corneal irritation, that was measured according to opacity test. A marked decrease in corneal opacity was observed using the drug formulated in nanoemulsions rather than in aqueous solutions. Drug permeation and accumulation studies were performed on excised rabbit corneas. An increase in drug permeation through and accumulation into the corneas were observed using TM-AOT compared to TM due to an increase of lipophilicity of the drug as ion-pair. The introduction of chitosan (a positive charged mucoadhesive polymer) into emulsions allowed to increase TM permeation probably due to the interaction of chitosan with corneal epithelial cells.
